Literature DB >> 31334547

Underlying molecular alterations in human dihydrolipoamide dehydrogenase deficiency revealed by structural analyses of disease-causing enzyme variants.

Eszter Szabo1, Piotr Wilk2, Balint Nagy1, Zsofia Zambo1, David Bui1, Andrzej Weichsel3, Palaniappa Arjunan4,5, Beata Torocsik1, Agnes Hubert1, William Furey4,5, William R Montfort3, Frank Jordan6, Manfred S Weiss2, Vera Adam-Vizi1, Attila Ambrus1.   

Abstract

Human dihydrolipoamide dehydrogenase (hLADH, hE3) deficiency (OMIM# 246900) is an often prematurely lethal genetic disease usually caused by inactive or partially inactive hE3 variants. Here we report the crystal structure of wild-type hE3 at an unprecedented high resolution of 1.75 Å and the structures of six disease-causing hE3 variants at resolutions ranging from 1.44 to 2.34 Å. P453L proved to be the most deleterious substitution in structure as aberrations extensively compromised the active site. The most prevalent G194C-hE3 variant primarily exhibited structural alterations close to the substitution site, whereas the nearby cofactor-binding residues were left unperturbed. The G426E substitution mainly interfered with the local charge distribution introducing dynamics to the substitution site in the dimer interface; G194C and G426E both led to minor structural changes. The R460G, R447G and I445M substitutions all perturbed a solvent accessible channel, the so-called H+/H2O channel, leading to the active site. Molecular pathomechanisms of enhanced reactive oxygen species (ROS) generation and impaired binding to multienzyme complexes were also addressed according to the structural data for the relevant mutations. In summary, we present here for the first time a comprehensive study that links three-dimensional structures of disease-causing hE3 variants to residual hLADH activities, altered capacities for ROS generation, compromised affinities for multienzyme complexes and eventually clinical symptoms. Our results may serve as useful starting points for future therapeutic intervention approaches.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31334547      PMCID: PMC7275779          DOI: 10.1093/hmg/ddz177

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  60 in total

1.  Studies on the kinetic mechanism of lipoamide dehydrogenase from rat liver mitochondria.

Authors:  J K Reed
Journal:  J Biol Chem       Date:  1973-07-10       Impact factor: 5.157

2.  Cryptic proteolytic activity of dihydrolipoamide dehydrogenase.

Authors:  Ngolela Esther Babady; Yuan-Ping Pang; Orly Elpeleg; Grazia Isaya
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-02       Impact factor: 11.205

3.  A multipronged approach unravels unprecedented protein-protein interactions in the human 2-oxoglutarate dehydrogenase multienzyme complex.

Authors:  Jieyu Zhou; Luying Yang; Oliver Ozohanics; Xu Zhang; Junjie Wang; Attila Ambrus; Palaniappa Arjunan; Roman Brukh; Natalia S Nemeria; William Furey; Frank Jordan
Journal:  J Biol Chem       Date:  2018-10-15       Impact factor: 5.157

4.  Structural and thermodynamic basis for weak interactions between dihydrolipoamide dehydrogenase and subunit-binding domain of the branched-chain alpha-ketoacid dehydrogenase complex.

Authors:  Chad A Brautigam; R Max Wynn; Jacinta L Chuang; Mandar T Naik; Brittany B Young; Tai-Huang Huang; David T Chuang
Journal:  J Biol Chem       Date:  2011-05-03       Impact factor: 5.157

5.  How dihydrolipoamide dehydrogenase-binding protein binds dihydrolipoamide dehydrogenase in the human pyruvate dehydrogenase complex.

Authors:  Ewa M Ciszak; Anna Makal; Young S Hong; Ananthalakshmy K Vettaikkorumakankauv; Lioubov G Korotchkina; Mulchand S Patel
Journal:  J Biol Chem       Date:  2005-11-01       Impact factor: 5.157

6.  A pH-dependent kinetic model of dihydrolipoamide dehydrogenase from multiple organisms.

Authors:  Michael A Moxley; Daniel A Beard; Jason N Bazil
Journal:  Biophys J       Date:  2014-12-16       Impact factor: 4.033

7.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

8.  Identification of a common mutation (Gly194Cys) in both Arab Moslem and Ashkenazi Jewish patients with dihydrolipoamide dehydrogenase (E3) deficiency: possible beneficial effect of vitamin therapy.

Authors:  Y S Hong; S H Korman; J Lee; P Ghoshal; Q Wu; V Barash; S Kang; S Oh; M Kwon; A Gutman; A Rachmel; M S Patel
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

9.  Riboflavin responsive mitochondrial myopathy is a new phenotype of dihydrolipoamide dehydrogenase deficiency. The chaperon-like effect of vitamin B2.

Authors:  Rosalba Carrozzo; Alessandra Torraco; Giuseppe Fiermonte; Diego Martinelli; Michela Di Nottia; Teresa Rizza; Angelo Vozza; Daniela Verrigni; Daria Diodato; Giovanni Parisi; Arianna Maiorana; Cristiano Rizzo; Ciro Leonardo Pierri; Stefania Zucano; Fiorella Piemonte; Enrico Bertini; Carlo Dionisi-Vici
Journal:  Mitochondrion       Date:  2014-09-22       Impact factor: 4.160

10.  Overview of the CCP4 suite and current developments.

Authors:  Martyn D Winn; Charles C Ballard; Kevin D Cowtan; Eleanor J Dodson; Paul Emsley; Phil R Evans; Ronan M Keegan; Eugene B Krissinel; Andrew G W Leslie; Airlie McCoy; Stuart J McNicholas; Garib N Murshudov; Navraj S Pannu; Elizabeth A Potterton; Harold R Powell; Randy J Read; Alexei Vagin; Keith S Wilson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18
View more
  2 in total

Review 1.  Dihydrolipoamide dehydrogenase, pyruvate oxidation, and acetylation-dependent mechanisms intersecting drug iatrogenesis.

Authors:  I F Duarte; J Caio; M F Moedas; L A Rodrigues; A P Leandro; I A Rivera; M F B Silva
Journal:  Cell Mol Life Sci       Date:  2021-10-31       Impact factor: 9.261

2.  Pyruvate dehydrogenase complex deficiency: updating the clinical, metabolic and mutational landscapes in a cohort of Portuguese patients.

Authors:  Hana Pavlu-Pereira; Maria João Silva; Cristina Florindo; Sílvia Sequeira; Ana Cristina Ferreira; Sofia Duarte; Ana Luísa Rodrigues; Patrícia Janeiro; Anabela Oliveira; Daniel Gomes; Anabela Bandeira; Esmeralda Martins; Roseli Gomes; Sérgia Soares; Isabel Tavares de Almeida; João B Vicente; Isabel Rivera
Journal:  Orphanet J Rare Dis       Date:  2020-10-22       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.